Lucid Diagnostics Inc (LUCD)

NASD · Healthcare · Medical Devices · USA

Lucid Diagnostics Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Lucid Diagnostics is a cancer prevention medical diagnostics company that offers EsoGuard, a DNA test performed on esophageal cells collected with the EsoCheck device. The test detects esophageal precancer in patients with chronic heartburn through a brief office procedure and is commercialized through physician offices, test centers, and direct-to-consumer channels.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Lucid Diagnostics Inc stock.

Our verdict on LUCD

Overvalued: intrinsic value $0.02 per share, market price $0.40, margin of safety -1698.6% (as of 2026-11-17).

A 0.9x revenue multiple, discounted for its losses, values the shares at $0.02; the price of $0.40 is 1699% above that value.

ETFs with the most weight in LUCD

8 more funds hold it; the full list is part of the paid plan.

More on LUCD

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than LUCD in Medical Devices

59 more in this industry show a wider margin of safety.

Is LUCD undervalued or overvalued?

LUCD is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $0.02; the price of $0.40 is 1699% above that value.

What is the intrinsic value of LUCD?

$0.02 per share (as of the 2026-11-17 close), against a market price of $0.40. That is a margin of safety of -1698.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.